Breaking News

Eurofins Genomics Gains ISO17025 Accreditation

August 15, 2014

Adds next-gen sequencing to testing portfolio

Eurofins Genomics has received ISO17025:2005 accreditation according to standards demonstrating high quality molecular testing. ISO 17025 is an international analytical standard used by testing and calibration labs covering mass spectrometry based DNA analysis and molecular testing methods. The company has been successfully accredited for the past seven years, and has been expanded to include more analytical applications.

Eurofins provides analytical testing services under the ISO17025 quality standard for applications in pharmaceutical testing, and in healthcare for medical lab testing for clinical studies and genetic diagnostics, as well as veterinary, food, feed and commodity testing. In April 2014, next generation sequencing (NGS) technologies based on Illumina and Roche 454 platforms were added to extend Eurofins’ ISO17025 service portfolio.

"The addition of our next generation sequencing services to our ISO17025 accreditation was the next logical step in response to our growing customer base in the regulated market and in areas with specific quality assurance needs," said Peter Persigehl, general manager Eurofins Genomics Europe.
blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Challenges in Global Biosimilar Development: A Regulatory Perspective

    Challenges in Global Biosimilar Development: A Regulatory Perspective

    Patricia Hurley, Joan Boren and Costantino Congiatu, PPD||June 2, 2015
    More than $60 billion worth of patents on biological products are expiring before 2020, representing a major opportunity for the pharmaceutical industry.